| Identification | Back Directory | [Name]
Cyclopropaneacetamide, N-[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl]-α-hydroxy-, (αS)- | [CAS]
2414254-36-5 | [Synonyms]
Cyclopropaneacetamide, N-[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl]-α-hydroxy-, (αS)- | [Molecular Formula]
C29H28FN3O6 | [MOL File]
2414254-36-5.mol | [Molecular Weight]
533.55 |
| Chemical Properties | Back Directory | [Boiling point ]
965.7±65.0 °C(Predicted) | [density ]
1.55±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
11.18±0.40(Predicted) | [color ]
Off-white to yellow |
| Hazard Information | Back Directory | [Uses]
Cyclopropaneacetamide-Exatecan (Compound 2-A) is an ADC Cytotoxin and an Exatecan analogue. Cyclopropaneacetamide-Exatecan can be used in the synthesis of ADC such as anti-B7H3 antibody-Exatecan analogue conjugate (compound ADC-2)[1]. | [IC 50]
Camptothecins | [References]
[1] Ying Hua, et al. Anti-b7h3 antibody-exatecan analog conjugate and medicinal use thereof. Patent WO2020063673A1. |
|
|